Natural immunity IS just as good as being jabbed: Official figures show unvaccinated Britons who beat Covid enjoy same protection against Delta as those who are double-dosed

Recovering from Covid offers just as good protection as getting two doses of any vaccine, official figures suggest. An Office for National Statistics' (ONS) report published today found unvaccinated Britons who catch the Delta variant are 71 per cent less likely to test positive a second time. It estimated the...
Picture for Natural immunity IS just as good as being jabbed: Official figures show unvaccinated Britons who beat Covid enjoy same protection against Delta as those who are double-dosed

Matinas BioPharma Initiates Dosing In Phase 1 Study Of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501

BEDMINSTER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced that it has dosed the first patient in a Phase 1 single ascending dose (SAD) pharmacokinetic study in healthy volunteers with MAT2501. The Company expects to complete enrollment of the Phase 1 SAD study in the first quarter of 2022, with data anticipated during the second quarter of 2022. Pending successful completion of the Phase 1 SAD study, the Company expects to start a Phase 2 program in patients with nontuberculous mycobacterial (NTM) infections by the first quarter of 2023, following required longer-term preclinical toxicology studies to be conducted during 2022.

How Do You Dose Cannabis Edibles?

It can be challenging to find your ideal dose of cannabis. Often this process requires some trial and error. With edibles, this can prove difficult, as getting it wrong may mean a whole day spent in bed waiting for things to get better. Fortunately, cannabis alone isn’t dangerous, and if you do take too much, the sensations won’t last. However, getting the dose wrong with edibles can be a bad experience you want to avoid.

MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN). IgAN, also known as Berger's disease, is a chronic and debilitating autoimmune disease affecting the kidneys and the most common glomerular disease worldwide. Currently there are no approved treatments that can specifically prevent the production of galactose-deficient IgA1 (Gd-IgA1) nor its corresponding autoantibody. 1.

PRESS RELEASE : MorphoSys AG: First Patient Dosed -2-

----------------------------------------------------------------------------------------------------------------------- 2021-10-20 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ----------------------------------------------------------------------------------------------------------------------- Language: English Company: MorphoSys AG Semmelweisstr....

First Patient With Squamous Cell Carcinoma Dosed in Phase 2 Trial for Vilobelimab

The first patient was enrolled and dosed in InflaRx’s phase 2 trial of vilobelimab for the treatment of cutaneous squamous cell carcinoma. It was announced in early June that InflaRx officially dosed its first patient in the phase 2 clinical trial evaluating vilobelimab for the treartment of PD-1 or PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC).

Travel industry, health experts applaud U.S. decision to allow travellers with mixed doses

TORONTO (CTV Network) — The organization representing Canada’s tourism industry is applauding the U.S. government’s decision to allow Canadian travellers with mixed vaccine doses once the border opens in November. On Friday, the U.S. Centers for Disease Control and Prevention confirmed that travellers with “any combination” of two doses of vaccines approved by the World Health Organization or the U.S. Food and Drug Administration “are considered fully vaccinated.” Beth Potter, who is president and CEO of the Tourism Industry Association of Canada, says the announcement is “really good news.” “What it does is it provides a little bit more clarity, and this is something that we’ve talked about a lot. We know now that if you’ve got that mixed dose, as of November you’re going to be able to enter into the United States,” she told CTV News Channel on Saturday. Infectious disease expert Isaac Bogoch of the University Health Network in Toronto says allowing mixed dosed travellers is “a smart and data driven approach.” “This will be a huge relief to many Canadians who did the right thing and got vaccinated and even took those mixed and matched vaccine approaches. It’s safe, it’s effective, and now there’s a recognition of this,” Bogoch said in an interview with CTV News Channel on Saturday. “I’m really happy to hear this. It’s about time.” This announcement came after the White House confirmed that the U.S. land borders with Canada and Mexico would be open to fully vaccinated tourists by Nov. 8. On the American side, the U.S. Travel Association also applauded the Biden Administration’s plans to reopen the border. “Reopening to international visitors will provide a jolt to the economy and accelerate the return of travel-related jobs that were lost due to travel restrictions,” said association president and CEO Roger Dow in a statement on Friday. “We applaud the administration for recognizing the value of international travel to our economy and our country, and for working to safely reopen our borders and reconnect America to the world.” But while the U.S. won’t require Canadians to show proof of vaccination to cross, returning to Canada requires a negative PCR test conducted at most 72 hours before crossing the border. PCR tests can cost upwards of $200. The Canadian government does not accept rapid antigen tests, which can be had for only $40. Brian Higgins, a New York congressman whose district includes the border cities of Buffalo and Niagara Falls, wants to see Canada drop the COVID-19 PCR test requirement. “I think that the U.S. decision to allow Canadians coming into the United States without a test again underscores the potency of the vaccine,” Higgins told The Canadian Press on Friday. “I would like to see that reciprocated by our Canadian neighbours.” However, Public Safety Minister Bill Blair said that Canada will continue to require PCR tests so long as the Public Health Agency of Canada advocates for it. “We’ve seen throughout the pandemic that advice has evolved as new evidence and new data is available. We’ll continue to follow the advice in the Public Health Agency Canada​,” he said in an ​interview with CTV’s Question Period on Sunday.

Dosing Begins in ACU193 Trial, Targeting Toxic Amyloid Beta

The first patient has been dosed in a Phase 1 trial testing ACU193, an antibody designed by Acumen Pharmaceuticals to target toxic forms of amyloid beta — called amyloid-beta oligomers — as a potential therapy for early Alzheimer’s disease. The INTERCEPT-AD Phase 1 trial (NCT04931459) is expecting to enroll approximately...

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

Phase IIa to explore the effectiveness of DMT in combination with psychotherapy for the potential treatment of Major Depressive Disorder. Program remains on track for topline results in H1 2022. October 19, 2021 - London, England - Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company...

Immune-Onc doses first patient in Phase I solid tumour treatment trial

Immune-Onc Therapeutics has dosed the first subject in the Phase I clinical trial of IO-108 to treat solid tumours. A new antagonist antibody, IO-108 acts on the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2 / ILT4). The multicentre, dose-escalation Phase I trial will analyse the tolerability, safety, pharmacokinetics, and pharmacodynamics...

NWHU begins giving out third doses

The Northwestern Health Unit has started doling out third doses of the COVID-19 vaccine to certain populations. People who are moderately to severely immunocompromised, and more recently, vulnerable elderly in congregate care settings are eligible to book their third dose of the vaccine. “We are working through the process of...